TP53 and neoplasm: Treatments with the JNK inhibitor have been reported to strongly induce CD95 expression, inducing apoptosis in six different tumor cell lines through p53- and p21-mediated G2/M cell cycle arrest, and caspase-8 and caspase-3 cleavage [53].